Alicia M. Douglas

Alicia M. Douglas

Auto-generated profile, based on publicly available information

Alicia M. Douglas

Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
EJEvangeline R. Jackson
Evangeline R. Jackson
RDRyan Duchatel
Ryan Duchatel
DSDilana E. Staudt
Dilana E. Staudt
MPMika L. Persson
Mika L. Persson
AMAbdul Mannan
Abdul Mannan
Matthew DunMatthew Dun
Matthew Dun
Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPG), are the most lethal of childhood cancers. Palliative radiotherapy is the only established treatment, with median patient survival of 9 to 11 months. ONC201 is a DRD2 antagonist and ClpP agonist that has shown preclinical and emerging clinical efficacy in DMG. However, further work is needed to identify the mechanisms of response of DIPGs to ONC201 treatment and to determine whether recurring genomic features influence response. Using a systems-biological approach, we showed that ONC201 elicits potent agonism of the mitochondrial protease ClpP to drive proteolysis of electron transport chain and tricarboxylic acid cycle proteins. DIPGs harboring PIK3CA mutations showed increased sensitivity to ONC201, whereas those harboring TP53 mutations were more resistant. Metabolic adaptation and reduced sensitivity to ONC201 was promoted by redox-activated PI3K/Akt signaling, which could be counteracted using the brain penetrant PI3K/Akt inhibitor, paxalisib. Together, these discoveries coupled with the powerful anti-DIPG/DMG pharmacokinetic and pharmacodynamic properties of ONC201 and paxalisib have provided the rationale for the ongoing DIPG/DMG phase II combination clinical trial NCT05009992. Significance: PI3K/Akt signaling promotes metabolic adaptation to ONC201-mediated disruption of mitochondrial energy homeostasis in diffuse intrinsic pontine glioma, highlighting the utility of a combination treatment strategy using ONC201 and the PI3K/Akt inhibitor paxalisib.

27 September 2022 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
TMTabitha McLachlan
Tabitha McLachlan
WMWilliam C. Matthews
William C. Matthews
EJEvangeline R. Jackson
Evangeline R. Jackson
DSDilana E. Staudt
Dilana E. Staudt
ADAlicia M. Douglas
Alicia M. Douglas
Matthew DunMatthew Dun
Matthew Dun
B-cell lymphoma 6 (BCL6) is a protooncogene in adult and pediatric cancers, first identified in diffuse large B-cell lymphoma (DLBCL) where it acts as a repressor of the tumor suppressor TP53, conferring survival, protection, and maintenance of lymphoma cells. BCL6 expression in normal B cells is fundamental in the regulation of humoral immunity, via initiation and maintenance of the germinal centers (GC). Its role in B cells during the production of high affinity immunoglobins (that recognize and bind specific antigens) is believed to underpin its function as an oncogene. BCL6 is known to drive the self-renewal capacity of leukemia-initiating cells (LIC), with high BCL6 expression in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and glioblastoma (GBM) associated with disease progression and treatment resistance. The mechanisms underpinning BCL6-driven therapy resistance are yet to be uncovered; however, high activity is considered to confer poor prognosis in the clinical setting. BCL6’s key binding partner, BCL6 corepressor (BCOR), is frequently mutated in pediatric cancers and appears to act in concert with BCL6. Using publicly available data, here we show that BCL6 is ubiquitously overexpressed in pediatric brain tumors, inversely to BCOR, highlighting the potential for targeting BCL6 in these often lethal and untreatable cancers. In this review, we summarize what is known of BCL6 (role, effect, mechanisms) in pediatric cancers, highlighting the two sides of BCL6 function, humoral immunity, and tumorigenesis, as well as to review BCL6 inhibitors and highlight areas of opportunity to improve the outcomes of patients with pediatric cancer.

28 March 2023 in Science Signaling
Verified
Journal Article
Closed access
ZGZacary P. Germon
Zacary P. Germon
JSJonathan R. Sillar
Jonathan R. Sillar
AMAbdul Mannan
Abdul Mannan
RDRyan Duchatel
Ryan Duchatel
DSDilana Staudt
Dilana Staudt
Matthew DunMatthew Dun
Matthew Dun
Mutations in the type III receptor tyrosine kinase FLT3 are frequent in patients with acute myeloid leukemia (AML) and are associated with a poor prognosis. AML is characterized by the overproduction of reactive oxygen species (ROS), which can induce cysteine oxidation in redox-sensitive signaling proteins. Here, we sought to characterize the specific pathways affected by ROS in AML by assessing oncogenic signaling in primary AML samples. The oxidation or phosphorylation of signaling proteins that mediate growth and proliferation was increased in samples from patient subtypes with FLT3 mutations. These samples also showed increases in the oxidation of proteins in the ROS-producing Rac/NADPH oxidase-2 (NOX2) complex. Inhibition of NOX2 increased the apoptosis of FLT3-mutant AML cells in response to FLT3 inhibitors. NOX2 inhibition also reduced the phosphorylation and cysteine oxidation of FLT3 in patient-derived xenograft mouse models, suggesting that decreased oxidative stress reduces the oncogenic signaling of FLT3. In mice grafted with FLT3 mutant AML cells, treatment with a NOX2 inhibitor reduced the number of circulating cancer cells, and combining FLT3 and NOX2 inhibitors increased survival to a greater extent than either treatment alone. Together, these data raise the possibility that combining NOX2 and FLT3 inhibitors could improve the treatment of FLT3 mutant AML.

17 May 2023
Verified
Other
Open access
PDF file
EJEvangeline R. Jackson
Evangeline R. Jackson
RDRyan Duchatel
Ryan Duchatel
DSDilana E. Staudt
Dilana E. Staudt
MPMika L. Persson
Mika L. Persson
AMAbdul Mannan
Abdul Mannan
Matthew DunMatthew Dun
Matthew Dun
All Supplementary Figures and their captions.

17 May 2023
Verified
Other
Open access
PDF file
EJEvangeline R. Jackson
Evangeline R. Jackson
RDRyan Duchatel
Ryan Duchatel
DSDilana E. Staudt
Dilana E. Staudt
MPMika L. Persson
Mika L. Persson
AMAbdul Mannan
Abdul Mannan
Matthew DunMatthew Dun
Matthew Dun
All Supplementary Figures and their captions.

16 September 2024
Verified
Other
Open access
EJEvangeline R. Jackson
Evangeline R. Jackson
RDRyan Duchatel
Ryan Duchatel
DSDilana E. Staudt
Dilana E. Staudt
MPMika L. Persson
Mika L. Persson
AMAbdul Mannan
Abdul Mannan
Matthew DunMatthew Dun
Matthew Dun
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma